Cassava 2.png
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
05 oct. 2023 09h15 HE | Cassava Sciences, Inc.
AUSTIN, Texas, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that Remi...
Cassava 2.png
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
02 oct. 2023 09h00 HE | Cassava Sciences, Inc.
804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical TrialA Second Pivotal Phase 3 Clinical Trial Is Expected to Complete Enrollment Q4 2023, With a Target Enrollment of Approximately...
Cassava 2.png
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
18 sept. 2023 09h15 HE | Cassava Sciences, Inc.
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials.The DSMB Recommended the Phase 3 Trials...
Cassava 2.png
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
13 sept. 2023 17h20 HE | Cassava Sciences, Inc.
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.Results corroborate prior research from other academic researchers.These data once...
Cassava 2.png
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
11 sept. 2023 09h10 HE | Cassava Sciences, Inc.
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.Results corroborate prior research from other academic researchers.These data once...
Cassava 2.png
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
06 sept. 2023 09h15 HE | Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it...
Cassava 2.png
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
03 août 2023 09h07 HE | Cassava Sciences, Inc.
Results of a randomized, controlled trial of oral simufilam in Alzheimer’s disease announced July 2023.Over 1,587 patients now enrolled in Phase 3 studies of simufilam in Alzheimer’s disease, an...
CHART 1
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
05 juil. 2023 09h15 HE | Cassava Sciences, Inc.
Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.Drug Effects Favored Mild Alzheimer’s Disease.In Mild Alzheimer’s,...
Cassava 2.png
New Research Shows Simufilam Suppresses Overactive mTOR
27 juin 2023 09h15 HE | Cassava Sciences, Inc.
Overactive mTOR Plays a Key Role in Aging and Alzheimer’s Disease.Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect.Research is Published in Frontiers in Aging, a Peer-reviewed...
Cassava 2.png
New Publication Highlights Basic Science Supporting Simufilam
12 juin 2023 09h15 HE | Cassava Sciences, Inc.
Publication Reviews Certain Receptor-Protein Interactions. Provides Overview of Basic Science Supporting Simufilam. Published in Drug Development Research, a Peer-Reviewed Journal. AUSTIN, Texas,...